

Supplementary Table 2:

Study cohort characteristics according to tPD-L1 (n = 313).

	pre-operative tPD-L1			post-operative tPD-L1			tPD-L1 change		
	<31.32 pg/mL	≥31.32 pg/mL	P Value	<20.24 pg/mL	≥20.24 pg/mL	P Value	<10.40 pg/mL	≥10.40 pg/mL	P Value
Number	156	157	-	156	157	-	156	157	-
Sex (Male, %)	107 (68.6)	112 (71.3)	0.597	113 (72.4)	106 (67.5)	0.344	100 (64.1)	119 (75.8)	0.024
Median age (Q1, Q3), year	59 (53, 67)	59 (53, 67)	0.860	58 (54, 66)	59 (54, 67)	0.437	60 (54, 68)	57 (53, 65)	0.017
Median BMI (Q1, Q3), kg/cm ²	23.0 (20.2, 26.1)	22.6 (20.6, 24.6)	0.246	23.3 (20.6, 26.6)	22.3 (20.3, 24.6)	0.011	22.8 (20.1, 24.8)	22.8 (20.6, 25.4)	0.828
Undifferentiated type (n, %)	60 (38.5)	69 (43.9)	0.326	57 (36.5)	72 (45.9)	0.094	57 (36.5)	72 (45.9)	0.094
Borrmann typing (III & IV, %)	84 (53.8)	115 (73.2)	0.001	87 (55.8)	111 (70.7)	0.004	98 (62.8)	100 (63.7)	0.966
T stage (T3-T4, %)	67 (42.9)	125 (79.6)	<0.001	74 (47.4)	118 (75.2)	<0.001	84 (53.8)	108 (68.8)	0.007
T1	62 (39.7)	18 (11.5)		54 (34.6)	26 (16.6)		47 (30.1)	33 (21.0)	
T2	27 (17.3)	14 (8.9)		28 (17.9)	13 (8.3)		25 (16.0)	16 (10.2)	
T3	60 (38.5)	71 (45.2)		53 (33.9)	78 (49.7)		68 (43.6)	63 (40.1)	
T4	7 (4.5)	54 (34.4)		21 (13.5)	40 (25.5)		16 (10.3)	45 (28.7)	
N stage (N1-N3, %)	59 (37.8)	95 (60.5)	<0.001	57 (36.5)	97 (61.8)	<0.001	70 (44.9)	84 (53.5)	0.128
N0	97 (62.2)	62 (39.5)		99 (63.5)	60 (38.2)		86 (55.1)	73 (46.5)	
N1	19 (12.2)	35 (22.3)		23 (14.7)	31 (19.7)		23 (14.7)	31 (19.7)	
N2	18 (11.5)	15 (9.6)		16 (10.3)	17 (10.8)		18 (11.5)	15 (9.6)	
N3	22 (14.1)	45 (28.7)		18 (11.5)	49 (31.2)		29 (18.6)	38 (24.2)	
M stage (M1, %)	15 (9.6)	18 (11.5)	0.596	12 (7.7)	21 (13.4)	0.102	18 (11.5)	15 (9.6)	0.569

TNM stage (stage3-4, %)	39 (25.0)	80 (50.9)	<0.001	40 (25.6)	79 (50.3)	<0.001	49 (31.4)	70 (44.6)	0.016
1	63 (40.4)	22 (14.0)		61 (39.1)	24 (15.3)		46 (29.5)	39 (24.8)	
2	54 (34.6)	55 (35.0)		55 (35.3)	54 (34.4)		61 (39.1)	48 (30.6)	
3	28 (17.9)	64 (40.8)		30 (19.2)	62 (39.5)		35 (22.4)	57 (36.3)	
4	11 (7.1)	16 (10.2)		10 (6.4)	17 (10.8)		14 (9.0)	13 (8.3)	
Concomitant disease (n, %)	69 (44.2)	53 (33.7)	0.058	57 (36.5)	65 (41.4)	0.379	76 (48.7)	46 (29.3)	<0.001
Type of gastrectomy (total, %)	69 (44.2)	84 (53.5)	0.101	76 (48.7)	77 (49.0)	0.954	71 (45.5)	82 (52.2)	0.236
Operation time, median (Q1, Q3), min	165 (140, 195)	180 (150, 210)	0.200	180 (150, 210)	170 (120, 195)	0.068	165 (120, 210)	180 (150, 210)	0.031
Intra-operative blood loss, median (Q1, Q3), mL	100 (100, 200)	100 (100, 200)	0.118	100 (100, 200)	100 (100, 200)	0.948	100 (100, 200)	100 (100, 200)	0.193
Lymphadenectomy (≥D2, %)	91 (58.3)	103 (65.6)	0.186	100 (64.1)	94 (59.9)	0.442	92 (59.0)	102 (65.0)	0.276
Adjuvant chemotherapy (n, %)	90 (57.7)	103 (65.6)	0.151	98 (62.8)	95 (60.5)	0.675	95 (60.9)	98 (62.4)	0.788
Post-operative complications (n, %)	17 (10.9)	32 (20.4)	0.021	22 (14.1)	27 (17.2)	0.453	20 (12.8)	29 (18.5)	0.170

The cut-off values for pre-operative, post-operative and change in tPD-L1 were defined according to corresponding median values. tPD-L1, plasma total PD-L1.